Scientific publications
-
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
-
Safety, Tolerability, and Clinical Effects of ZP8396, an Amylin Analog: Multiple Ascending Dose Trial
-
Potent Weight Loss Effects of Amylin Analog ZP8396 in Combination with Tirzepatide in DIO Rats
-
Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial
-
Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long Acting Amylin Analog: A Single Ascending Dose Rrial
-
Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial
-
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906
-
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
-
Amylin Analog ZP8396 Co-formulated With Semaglutide Provides Additive Anti-obesity Effect in DIO Rat
-
Effect of Dapiglutide Alone and in Combination with the Amylin Analog ZP8396 in the Diet-induced Obesity Rat Model
